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ABSTRACT
Background: Prostate cancer diagnosis is routinely made
by the histopathological examination of formalin fixed
needle biopsy specimens. Frequently this is the only
cancer tissue available from the patient for the analysis of
diagnostic and prognostic biomarkers. There is, therefore,
an urgent need for methods that allow the high-
throughput analysis of these biopsy samples using
immunohistochemical (IHC) markers and fluorescence in
situ hybridisation (FISH) analysis based markers.
Methods: A method that allows the construction of
tissue microarrays (TMAs) from diagnostic prostate
needle biopsy cores has previously been reported.
However, the technique only allows the production of
low-density biopsy TMAs with a maximum of 20 cores
per TMA. Here two methods are presented that allow the
rapid and uniform production of biopsy TMAs containing
between 54 and 72 biopsy cores. IHC and FISH
techniques were used to detect biomarker status.
Results: Biopsy TMAs were constructed from prostate
needle biopsy specimens taken from 102 patients entered
into an active surveillance trial and 201 patients in a
radiotherapy trial. The detection rate for cancer in slices of
these biopsy TMAs was 66% and 79% respectively. Slices
of a biopsy TMA prepared from biopsies from active
surveillance patients were used to detect multiple IHC
markers and to score TMPRSS2-ERG fusion status in a
FISH-based assay.
Conclusions: The construction of biopsy TMAs provides
an effective method for the multiplex analysis of IHC and
FISH markers and for their assessment as prognostic
biomarkers in the context of clinical trials.
Prostate cancer is the commonest cancer diagnosed
in men in Western societies with over 200 000
cases diagnosed each year in the USA alone.
Unfortunately established prognostic factors
(Gleason score, T stage, blood PSA, cancer volume)
are inadequate for predicting the precise clinical
behaviour of individual patients, and there is an
urgent need for new biomarker discovery. In order
to test new biomarkers needle biopsy specimens
taken at the time of diagnosis have been used in
molecular profiling of cancer specimens, with Khor
et al,
12for example, using sections of the entire
length of the formalin biopsy specimen to examine
prognostic markers in patients with prostate
cancer. Singh et al
3 showed that the conventional
tissue microarray (TMA) construction techniques
described by Kononen et al
4 can be used to punch
out regions of the needle biopsy specimen that
contained cancer and create high density arrays.
However, both of these techniques are limited in
that the number of slices that can be taken for
biomarker analysis is limited by the width of the
biopsy. In an alternative approach
5–7 we have re-
orientated the biopsies into a vertical orientation
allowing construction of biopsy TMAs and the
analysis of the markers in cross sections taken from
each biopsy. An alternative method of biopsy TMA
production has also been described by Datta et al,
8 in
which the biopsy iscut offthe surface ofthe paraffin
block, held with forceps, and placed in a hole that
has been bored in a recipient wax block. A limitation
of our original technique
5 is that a maximum of 20
biopsy specimens could be included within each
TMA. A particular problem is thatthe cutting out of
small regular ‘‘checkers’’ of wax containing a
segment of the biopsy on one face, which is required
for the construction of the biopsy TMA, is
technically demanding and time consuming.
5 Here
we present a simplified technique for cutting wax
checkers, and describe methods for constructing
biopsy TMAs containing 54–72 checkers. The
success rates for constructing biopsy TMAs from
patients undergoing radiotherapy and entered into
active surveillance trials are reported.
MATERIALS AND METHODS
Clinical samples
Men with untreated, localised (clinical stage T1/2a,
Gleason score (3+4; PSA ,15; (50% positive
cores)prostatecancerweremanagedinaprospective
study of active surveillance at the Royal Marsden
Hospital NHS Foundation Trust. The methods used
for selecting samples for biopsy TMA construction
from prostate cancer patients entered into active
surveillance and from the MRC RT01 radiotherapy
trial have been described previously.
67All patients
gave their written consent to take part in the active
surveillance and radiotherapy studies, which were
approved by the local research ethics committee.
Construction of biopsy tissue microarrays
Two methods were used to construct biopsy
TMAs. The two methods differ primarily in the
shape and construct of the template used to
accommodate the checkers and the method of
embedding. The first method utilised a rubber mould
that contained 54 4 mm deep, 2 mm62 mm square
rubberpegs(figure3B,supplementaryfig1).Thepegs
arespaced1 mmapart.Therubbermouldwasplaced
in a disposable wax mould (E10.6/2001/33, RA Lamb,
UK) and an embedding cassette (E10, RA Lamb, UK)
was positioned over the top (supplementary fig 1A–
C). Paraffin wax (W1, RA Lamb, UK) at 60uCw a s
distributed in the wax mould while the cassette was
held in position by forceps (supplementary fig 1D,E).
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a n dt h e ni naf r e e z e ra t220uC (supplementary fig 1F,G). The
resulting wax template construct accommodates 54 separate
checkers (fig 3A,C). In the second method, the rubber mould
contained three larger 4 mm deep pegs of 10 mm620 mm,
8m m 620 mm and 6 mm620 mm (fig 3F). Paraffin wax at 60uC
was distributed with a tissue embedding station (Microm EC350,
Thermo-Fisher, UK) into an aluminium mould base (supplemen-
tary fig 2A) and the rubber mould was then pressed firmly into the
wax and placed on a cold plate (215uC) (Microm EC350-2,
Thermo-Fisher,UK)andallowedtosolidify(fig 3E, supplementary
figure2B,C).Aluminiummouldbaseandrubbermouldinsertswere
constructed by the Institute of Cancer Research workshops. The
rubber mould inserts were made from RTV (room temperature
vulcanising) rubber (EMA Model Supplies, UK). Wax checkers
madeas describedin the text wereinserted into the wax templates
asshowninsupplementaryfig3.Themethodsforbindingthewax
of thecheckersand templates are described insupplementaryfig 3.
Immunohistochemical and FISH analysis
Sectioning and preparation of biopsy TMA blocks has been
described previously.
5 Fluorescence in situ hybridisation (FISH)
detection of ERG gene status was carried out exactly as
described previously.
91 0 Immunohistochemical analysis for
H&E, p63/AMACR, Ki-67 and Hif1-a staining were performed
exactly as described previously.
61 1
RESULTS
An improved method for the preparation of individual blocks or
‘‘checkers’’
The starting point for construction of biopsy TMAs is a paraffin
block containing one or more formalin fixed prostate needle
Figure 1 Knives used for cutting biopsy checkers. The knives each
consist of parallel surgical blades fixed in translucent acrylic plastic. The
figure shows knives with the blades 4 mm apart (A, B) and 2 mm apart
(C, D).
Figure 2 Construction of biopsy checkers. For clarity the formalin fixed prostate cancer needle biopsy has been coloured green. The position of the
4 mm length of biopsy on the surface of the wax block selected for checker construction is marked (A). The knife containing parallel blades 4 mm apart
(fig 1A, B) is positioned over the wax block (B, C) so that a 4 mm length of biopsy is cut (D, E). A scalpel blade is used to cut the section of wax
containing the attached 4 mm biopsy segment from the block (F). For orientation the side of the checker is marked with red ink (G). The knife containing
blades 2 mm apart (fig 1C, D) is then used to make two further cuts (H–J) and for orientation an additional face of the checker is marked with blue ink
(K). The final 4 mm62m m 62 mm checker is shown (L). The marking of faces of the checker with red and blue ink is important because it is often
difficult to visualise the biopsy specimen as the checker is being cut. The entire process of checker construction takes approximately 5 minutes.
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J Clin Pathol 2009;62:694–698. doi:10.1136/jcp.2009.065201 695Figure 3 Construction of wax templates. Wax templates were constructed to accommodate 4 mm62m m 62 mm wax checkers. Two formats were
used. In the first format (A–D) individual wells were created into which a single checker could be placed. In the second format (E–H) three larger wells
(6 mm620 mm, 8 mm620 mm and 10 mm620 mm) were created which together accommodated 72 checkers. The rubber moulds used to construct
each template are shown respectively in (B) and (F). The detailed methods for constructing the wax templates are shown in supplementary figs 1 and 2.
The methods used to insert individual checkers into the templates are shown in supplementary fig 3. (C, G) Completed biopsy tissue microarrays. (D, H)
H&E stained sections of each biopsy tissue microarray (TMA). A black cross and black circle denote the position of a blank checker and of a
representative biopsy core, respectively. The construction of the entire biopsy TMA from formalin fixed biopsy specimens takes 2 days.
Figure 4 Analysis of sections obtained from a biopsy tissue microarray (TMA). Left panel: Serial sections (620) from a single biopsy specimen that
contained both cancer (surrounded by thick line) and non-neoplastic epithelium (surrounded by dashed line) stained by H&E, p63/AMACR Ki-67 and Hif-
1a. The insert shows a magnification of the Ki67 staining. Right panel: FISH detection of ERG gene breakpoints. (A) Principle of detection of ERG gene
status. Interphase nuclei are hybridised to probes that detect sequences 59 to the ERG gene (green) and 39 to the ERG gene (red). (B, C) Results from
biopsy TMA slices. The red and green co-localise for normal ERG loci (B) and are separated (C) when an ERG gene rearrangement occurs.
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is examined to confirm the diagnosis of prostate cancer and to
identify the location of the cancer within the biopsy. In the
original method
5 small checkers (approx 4 mm62m m 62 mm)
containing a 4 mm length of the biopsy specimen were roughly
cut from the block with a scalpel blade. To improve the
uniformity of the size of the checker and the speed of
production we have devised a cutting system using the knives
shown in fig 1. A Perspex block containing two parallel blades
4 mm apart (fig 1A,B) is first used to make cuts that define a
4 mm length of biopsy (fig 2B–E). Next a scalpel is used to cut
away excess wax (fig 2F). A second cutting tool with blades
2 mm apart (fig 1C,D) is used to make a second cut parallel to
the biopsy along the positions of the remaining two black lines
(fig 2G,H). The resulting wax block is turned on its side and a
final cut with the same knife results in the
4m m 62m m 62 mm checker (fig 2I–L). Sides of the checker
are marked with red and blue as illustrated during the cutting
process to keep track of the position of the face of the checker
with the attached biopsy (fig 2G,K).
Construction of biopsy tissue microarrays
The uniformity in size of the checkers produced by this
procedure enabled us to increase the density of biopsy
specimens in each TMA. In one method a wax receptacle block
was constructed that contained 54 individual 2 mm62m m
wells (fig 3A); a single checker is placed in each well. In a second
method the wax template contains three rectangular wells of
6m m 620 mm, 8 mm620 mm and 10 mm620 mm that
together accommodate 72 checkers (fig 3E). The rubber moulds
used for constructing these two templates are shown in fig 3B
and 3F, respectively, and the detailed methods for constructing
the template are shown in supplementary figs 1 and 2.
Following packing of the checkers into the template, warming
fuses the wax of the template and checkers into a single block.
Examples of biopsy TMAs constructed using these two methods
are show in fig 3C and 3G, and the corresponding H&E stained
sections are shown in fig 3D and 3H. To ensure that each TMA
exhibited a unique pattern of cores, up to 14 blank wax checkers
(a blank wax checker lacks an attached biopsy core) were
included in each TMA (indicated by a black cross in fig 3). An
example of a malignant core from these TMAs sliced and
stained with H&E, p63/AMACR (p63/alpha-methylacyl-CoA
racemase), Ki-67 and Hif-1a (hypoxia-inducible factor 1, alpha
subunit) are shown in fig 4. Around 60% of prostate cancers are
reported to contain fusions of the androgen regulated gene
TMPRSS2 to ERG
9 11–14 which causes high level expression of 39-
ERG gene sequences. In previous studies we have shown that a
FISH-based break-apart assay may be used to detect ERG gene
status in slices taken from conventional TMAs.
91 0The same
assay can be used to detect ERG-gene rearrangements in slices of
biopsy TMAs (fig 4A–C).
Efficiency of analyses using biopsy TMAs
In re-analyses of our previous datasets
7 collected using biopsy
TMAs produced using the original construction technique, we
found that of 102 active surveillance patients, 62 yielded cancer
that was visible in slices of the biopsy TMA (efficiency=61%).
To assess cancer we examined H&E stained slices 1, 10 and 20
taken from the biopsy TMA: cancer must be present in one or
more of these three slices. This low success rate is accounted for
because 38 patients had low volume cancer (less than 10% of
cancer glands in the original biopsy core). The comparable
success rate for biopsies from our previously published study in
the MRC RT01 radiotherapy trial,
6 again using biopsy TMAs
produced using our original construction procedure, was 79%.
Using the new construction procedure described here the
detection rate for cancer in biopsies taken from active
surveillance patients was 66%. There were no discernable
differences in immunohistochemical results obtained using the
old and new biopsy TMA construction techniques.
DISCUSSION
Over 60 biomarkers have been linked to poorer clinical outcome
of human prostate cancer.
15 However with the exception of
serum PSA, none are routinely used in the risk classification of
this disease. This is in part a reflection of the inability to rapidly
test biomarkers in the precise setting in which they would be
used clinically. We have developed a procedure for producing
TMAs from prostate cancer needle biopsies taken at the time of
diagnosis.
5 Analysis using this technique allows biomarkers to
be examined in clinical specimens taken at the time of diagnosis
in patients entered into clinical trials. Indeed we have now
confirmed the utility of this approach through analysis of
biomarkers in active surveillance trials
7 and in radiotherapy
trials.
6 However our original approach
5 was limited because only
20 biopsy cores could be assembled in a single biopsy TMA. In
this study we show that through a combination of the
development of methods for cutting consistently shaped
checkers, and the use of wax templates we can increase this
density up to 72 biopsies in each biopsy TMA. This three and a
half-fold increase in density reduces the number of TMA slices
that need to be produced and examined, and the application of
this approach to patients in active surveillance trials has allowed
us to construct five biopsy TMAs that contained 287 cores from
108 patients. The construction of TMAs from prostate needle
biopsy specimens also allows the multiplex analysis of
biomarkers. This is critical because it is likely to be the analysis
of a combination of markers rather than of a single marker that
will provide the best prognostic information.
16 In this respect in
the context of a radiotherapy trial,
6 we initially tested three
markers (Hif-1a, VEGF and osteopontin) in 201 patients, and
the analysis of additional markers is in progress. In conclusion,
the methods presented here provided a cheap and simple
procedure for constructing TMAs from prostate needle biopsy
specimens that allows multiplex analysis of biomarkers in the
context of clinical trials.
Take-home messages
c There is an urgent need to identify new biomarkers that will
aid in improved targeting of radical treatments in patients with
prostate cancer.
c To identify such biomarkers it is essential to perform tests on
samples taken from the patient at the time of diagnosis, which
usually only include blood, urine and trans-ultrasound guided
prostate needle biopsy samples.
c A novel method is presented that allows the rapid and uniform
production of tissue microarrays from needle biopsies taken
from the prostate at the time of cancer diagnosis.
c The biopsy TMAs produced can be used for the multiplex
analysis of potential biomarkers detected by
immunohistochemistry or by fluorescence in situ hybridisation
in prostate needle biopsies taken from patients entered into
clinical trials.
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